2026 Q3 - tulosraportti
UUTTA
1 päivä sitten
‧1 t 2 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 18 | ||
| 104 | ||
| 200 | ||
| 200 | ||
| 200 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 17.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 5.11. | ||
2026 Q2 - tulosraportti 6.8. | ||
2026 Q1 - tulosraportti 7.5. | ||
2025 Q4 - tulosraportti 17.2. | ||
2025 Q3 - tulosraportti 6.11.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·3 t sittenHi 😊 I am still quite new to this stock thing and would like to hear how you, who have followed Genmab longer, read today's financial report. I bought around share price 2,060, and my plan was actually to sell when I was 24,000 DKK in profit. I am well past that goal now, so I am considering whether I should take some of the profit or keep the shares a little longer. I think it sounds exciting with Epkinly, Rina-S, and petosemtamab, and that Genmab talks about possible launches in 2027. How much of that potential do you think is already priced into the stock after the big increase? And what will you especially keep an eye on to assess whether the stock has more to give? I am asking a bit cautiously, because I am no stock shark 😅 I just want to understand how you others think about this one from here.🙏🏼
·5 t sitten · MuokattuIt was as expected quite close to being a non-event earnings report and CC today, after the enormously positive data from October (this written, as I also followed the CC after ESMO thereby getting close to double up) Would naturally encourage everyone to listen to today's presentation, so you know the company behind the share price. Of course there were no guides for 2027 and also no news about potential upcoming applications. As previously written, it will probably be quiet for the next period and then we will hear from Genmab in early 2027, once Genmab has had the dialogue with FDA and EMA. Those who are waiting for FDA might be disappointed with that timeline, but that is just how it works. 2027 will be exciting with 3 potential launches, but we will probably have to move into 2028 and 2029 before we see increased growth on the top line and hopefully a greater acceleration on the bottom line. There will hardly be any significant changes to any estimates after today. Good evening
From Børsen: "Epkinly, Rina and Peto are all fantastic medicines. We know that they can achieve things we haven't seen before," says Jan van de Winkel about the treatments for lymphoma, ovarian cancer, and head and neck cancer, respectively. With these three winners, I hope that we can indeed grow quite effectively, even if we lose the exclusivity rights to Darzalex by the end of this decade. All the prerequisites are in place," says Jan van de Winkel. https://borsen.dk/nyheder/virksomheder/genmab-topchef-droftede-opjustering-med-bestyrelse?b_source=borsen&b_medium=row_0&b_campaign=news_2
·7 t sittenGenmab delivers solid growth in nine-month report – maintains guidance for 2026 https://proinvestor.com/nyheder/genmab-leverer-solid-vkst-i-ni-mneders-regnskab--fastholder-forventninger-for-2026
·8 t sittenWow, an outstanding third quarter on all fronts – tune in at 18:00.
Agreed, though over a wide range below analysts' expectations. However, relatively limited, but it is impacting the share price in the US. Let's hope they have something extra good in the bag to tell at 18:00 on the CC.- ·8 t sittenFor those interested in more than just the price chart :-) Earnings report after 17.00 and CC at 18.00 with management's presentation of Q3 and Q&A per the link below. https://edge.media-server.com/mmc/p/au5j2bbj/lan/en/ (There should be no conflict with daylight saving time this time, which "unfortunately" caused a 1-hour shift during the last CC)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q3 - tulosraportti
UUTTA
1 päivä sitten
‧1 t 2 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·3 t sittenHi 😊 I am still quite new to this stock thing and would like to hear how you, who have followed Genmab longer, read today's financial report. I bought around share price 2,060, and my plan was actually to sell when I was 24,000 DKK in profit. I am well past that goal now, so I am considering whether I should take some of the profit or keep the shares a little longer. I think it sounds exciting with Epkinly, Rina-S, and petosemtamab, and that Genmab talks about possible launches in 2027. How much of that potential do you think is already priced into the stock after the big increase? And what will you especially keep an eye on to assess whether the stock has more to give? I am asking a bit cautiously, because I am no stock shark 😅 I just want to understand how you others think about this one from here.🙏🏼
- ·5 t sitten · MuokattuIt was as expected quite close to being a non-event earnings report and CC today, after the enormously positive data from October (this written, as I also followed the CC after ESMO thereby getting close to double up) Would naturally encourage everyone to listen to today's presentation, so you know the company behind the share price. Of course there were no guides for 2027 and also no news about potential upcoming applications. As previously written, it will probably be quiet for the next period and then we will hear from Genmab in early 2027, once Genmab has had the dialogue with FDA and EMA. Those who are waiting for FDA might be disappointed with that timeline, but that is just how it works. 2027 will be exciting with 3 potential launches, but we will probably have to move into 2028 and 2029 before we see increased growth on the top line and hopefully a greater acceleration on the bottom line. There will hardly be any significant changes to any estimates after today. Good eveningFrom Børsen: "Epkinly, Rina and Peto are all fantastic medicines. We know that they can achieve things we haven't seen before," says Jan van de Winkel about the treatments for lymphoma, ovarian cancer, and head and neck cancer, respectively. With these three winners, I hope that we can indeed grow quite effectively, even if we lose the exclusivity rights to Darzalex by the end of this decade. All the prerequisites are in place," says Jan van de Winkel. https://borsen.dk/nyheder/virksomheder/genmab-topchef-droftede-opjustering-med-bestyrelse?b_source=borsen&b_medium=row_0&b_campaign=news_2
- ·7 t sittenGenmab delivers solid growth in nine-month report – maintains guidance for 2026 https://proinvestor.com/nyheder/genmab-leverer-solid-vkst-i-ni-mneders-regnskab--fastholder-forventninger-for-2026
- ·8 t sittenWow, an outstanding third quarter on all fronts – tune in at 18:00.Agreed, though over a wide range below analysts' expectations. However, relatively limited, but it is impacting the share price in the US. Let's hope they have something extra good in the bag to tell at 18:00 on the CC.
- ·8 t sittenFor those interested in more than just the price chart :-) Earnings report after 17.00 and CC at 18.00 with management's presentation of Q3 and Q&A per the link below. https://edge.media-server.com/mmc/p/au5j2bbj/lan/en/ (There should be no conflict with daylight saving time this time, which "unfortunately" caused a 1-hour shift during the last CC)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 18 | ||
| 104 | ||
| 200 | ||
| 200 | ||
| 200 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 17.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 5.11. | ||
2026 Q2 - tulosraportti 6.8. | ||
2026 Q1 - tulosraportti 7.5. | ||
2025 Q4 - tulosraportti 17.2. | ||
2025 Q3 - tulosraportti 6.11.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q3 - tulosraportti
UUTTA
1 päivä sitten
‧1 t 2 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 17.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 5.11. | ||
2026 Q2 - tulosraportti 6.8. | ||
2026 Q1 - tulosraportti 7.5. | ||
2025 Q4 - tulosraportti 17.2. | ||
2025 Q3 - tulosraportti 6.11.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·3 t sittenHi 😊 I am still quite new to this stock thing and would like to hear how you, who have followed Genmab longer, read today's financial report. I bought around share price 2,060, and my plan was actually to sell when I was 24,000 DKK in profit. I am well past that goal now, so I am considering whether I should take some of the profit or keep the shares a little longer. I think it sounds exciting with Epkinly, Rina-S, and petosemtamab, and that Genmab talks about possible launches in 2027. How much of that potential do you think is already priced into the stock after the big increase? And what will you especially keep an eye on to assess whether the stock has more to give? I am asking a bit cautiously, because I am no stock shark 😅 I just want to understand how you others think about this one from here.🙏🏼
- ·5 t sitten · MuokattuIt was as expected quite close to being a non-event earnings report and CC today, after the enormously positive data from October (this written, as I also followed the CC after ESMO thereby getting close to double up) Would naturally encourage everyone to listen to today's presentation, so you know the company behind the share price. Of course there were no guides for 2027 and also no news about potential upcoming applications. As previously written, it will probably be quiet for the next period and then we will hear from Genmab in early 2027, once Genmab has had the dialogue with FDA and EMA. Those who are waiting for FDA might be disappointed with that timeline, but that is just how it works. 2027 will be exciting with 3 potential launches, but we will probably have to move into 2028 and 2029 before we see increased growth on the top line and hopefully a greater acceleration on the bottom line. There will hardly be any significant changes to any estimates after today. Good eveningFrom Børsen: "Epkinly, Rina and Peto are all fantastic medicines. We know that they can achieve things we haven't seen before," says Jan van de Winkel about the treatments for lymphoma, ovarian cancer, and head and neck cancer, respectively. With these three winners, I hope that we can indeed grow quite effectively, even if we lose the exclusivity rights to Darzalex by the end of this decade. All the prerequisites are in place," says Jan van de Winkel. https://borsen.dk/nyheder/virksomheder/genmab-topchef-droftede-opjustering-med-bestyrelse?b_source=borsen&b_medium=row_0&b_campaign=news_2
- ·7 t sittenGenmab delivers solid growth in nine-month report – maintains guidance for 2026 https://proinvestor.com/nyheder/genmab-leverer-solid-vkst-i-ni-mneders-regnskab--fastholder-forventninger-for-2026
- ·8 t sittenWow, an outstanding third quarter on all fronts – tune in at 18:00.Agreed, though over a wide range below analysts' expectations. However, relatively limited, but it is impacting the share price in the US. Let's hope they have something extra good in the bag to tell at 18:00 on the CC.
- ·8 t sittenFor those interested in more than just the price chart :-) Earnings report after 17.00 and CC at 18.00 with management's presentation of Q3 and Q&A per the link below. https://edge.media-server.com/mmc/p/au5j2bbj/lan/en/ (There should be no conflict with daylight saving time this time, which "unfortunately" caused a 1-hour shift during the last CC)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 18 | ||
| 104 | ||
| 200 | ||
| 200 | ||
| 200 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt